https://www.selleckchem.com/pr....oducts/epalrestat.ht
Proteasome inhibitors (PI) bortezomib or carfilzomib among them, play a crucial role in the modern standard therapy for multiple myeloma (MM). In this study, we intended to evaluate whether immunoproteasome (IMP) concentration could act as an effective biomarker which determines the probability of response to treatment with bortezomib, in order to detect groups of patients who are more likely to respond to treatment with PI. In our study, we evaluated IMP concentration in the plasma of 40 patients with monoclonal gammopathy of undete
Like
Comment
Share
